Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108485 · ClinicalTrials.gov registry record · Phase 3
Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy
A Phase 3 study, sponsored by University of Miami.
- Terminated
- Registry status
- Phase 3
- Development phase
- 9
- Enrollment target
NCT00108485 is a Phase 3 study that was terminated before completion, run by University of Miami. The registered enrollment target is 9 participants.
The verdict
NCT00108485, a Phase 3 study, was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 9 participants
- Enrollment target
Study Summary
The primary purpose of this study is to test the effectiveness and tolerability of Niaspan® to improve the levels of blood fats ("good" and "bad" cholesterol and triglyceride levels) in people who have kidney damage due to diabetes. A secondary goal is to test whether Niaspan® slows down further development of kidney damage.
Interventions
- OTHER Placebo
- DRUG Extended release niacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2005-04 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00108485
The ClinicalTrials.gov registry entry for NCT00108485 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00108485 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00108485 about?
NCT00108485 is a clinical study titled "Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy". The primary purpose of this study is to test the effectiveness and tolerability of Niaspan® to improve the levels of blood fats ("good" and "bad" cholesterol and triglyceride levels) in people who have kidney damage due to diabetes. A secondary goal is to test whether Niaspan® slows down further dev...
What is the current status of trial NCT00108485?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 9 participants. The study started on 2005-04. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00108485?
The interventions under investigation include: Placebo (OTHER), Extended release niacin (DRUG).
Who is sponsoring clinical trial NCT00108485?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.